Search results
Can England get to the final playing like this?
The New Statesman· 6 hours agoSince 1966, whenever a World Cup or European Championship came along, I said the same thing to my wife. By chance this summer I have been back in...
Eli Lilly Remains an Equities Outlier
FX Empire via Yahoo Finance UK· 2 days agoIt’s no wonder LLY shares are up 54% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the...
Your memories of the places Mancunians got up to mischief with mates during summer holidays gone by
Manchester Evening News via Yahoo News UK· 1 hour agoMaria Lilly Rose, remembered: "Oh I remember the Witch's Tunnel. My auntie took me through it when I...
FDA approves a second Alzheimer's drug that can modestly slow disease
Associated Press via Yahoo News UK· 5 days agoThe Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of...
Here's what actually happened in the misunderstood Lost finale
The Independent· 4 days agoThe logic is that, should the hatch never be created, Oceanic Flight 815 will never crash on the...
New Drug Approved for Early Alzheimer’s
New York Times· 5 days agoThe drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the...
FDA approves Eli Lilly's treatment which slows symptoms down
Daily Mail· 5 days agoThe US FDA has approved donanemab, a treatment for Alzheimer's disease that helps the body remove...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 4 days agoLilly Biotechnology Center in San Diego, Calif. Credit - Getty Images On July 2, the U.S. Food and...
Lost: The alternative series ending the writers almost used
The Independent· 9 hours agoThe ending of Lost is the most misunderstood series finale in television history – but it almost...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
CNN via Yahoo News UK· 5 days agoThe US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.